MX389553B - Composicion para incrementar la expresion de pgc-1alfa - Google Patents
Composicion para incrementar la expresion de pgc-1alfaInfo
- Publication number
- MX389553B MX389553B MX2018008671A MX2018008671A MX389553B MX 389553 B MX389553 B MX 389553B MX 2018008671 A MX2018008671 A MX 2018008671A MX 2018008671 A MX2018008671 A MX 2018008671A MX 389553 B MX389553 B MX 389553B
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- pgc
- increasing expression
- expression
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160004383 | 2016-01-13 | ||
| PCT/KR2017/000505 WO2017123066A1 (ko) | 2016-01-13 | 2017-01-13 | Pgc-1알파의 발현을 증가시키는 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008671A MX2018008671A (es) | 2019-02-13 |
| MX389553B true MX389553B (es) | 2025-03-20 |
Family
ID=59311711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008671A MX389553B (es) | 2016-01-13 | 2017-01-13 | Composicion para incrementar la expresion de pgc-1alfa |
| MX2022000945A MX2022000945A (es) | 2016-01-13 | 2018-07-13 | Composicion para incrementar la expresion de pgc-1alfa. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000945A MX2022000945A (es) | 2016-01-13 | 2018-07-13 | Composicion para incrementar la expresion de pgc-1alfa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190030053A1 (enExample) |
| EP (2) | EP3403655B1 (enExample) |
| JP (3) | JP7125348B2 (enExample) |
| KR (3) | KR20180099885A (enExample) |
| CN (3) | CN120643579A (enExample) |
| CA (2) | CA3010338C (enExample) |
| ES (1) | ES2946945T3 (enExample) |
| HK (1) | HK1257689A1 (enExample) |
| MX (2) | MX389553B (enExample) |
| MY (1) | MY197561A (enExample) |
| SG (1) | SG11201805791RA (enExample) |
| WO (1) | WO2017123066A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3498282A1 (en) * | 2017-12-12 | 2019-06-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | 6'-sialyllactose for use in the treatment of hearing loss |
| US11234992B2 (en) * | 2018-02-28 | 2022-02-01 | The Regents Of The University Of California | Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides |
| AU2020230410A1 (en) * | 2019-03-05 | 2021-09-02 | Société des Produits Nestlé S.A. | A nutritional composition for use to enhance executive function |
| MX2021010289A (es) * | 2019-03-05 | 2022-02-10 | Glycom As | Oligosacaridos de leche humana para uso en el mejoramiento de la funcion ejecutiva. |
| JP2021038147A (ja) * | 2019-08-30 | 2021-03-11 | 国立大学法人 鹿児島大学 | ミトコンドリア生合成促進剤 |
| KR102186761B1 (ko) * | 2020-06-03 | 2020-12-04 | 옙바이오 주식회사 | 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물 |
| GB202114190D0 (en) * | 2021-10-04 | 2021-11-17 | Mjn Us Holdings Llc | Compositions for preventing and/or treating demyelination |
| CN121100111A (zh) * | 2023-06-02 | 2025-12-09 | 兹杜斯生命科学有限公司 | 用于肌萎缩侧索硬化(als)的治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164374A (en) * | 1990-12-17 | 1992-11-17 | Monsanto Company | Use of oligosaccharides for treatment of arthritis |
| JPH07258093A (ja) * | 1994-03-23 | 1995-10-09 | Morinaga Milk Ind Co Ltd | 神経成長因子様剤 |
| KR101116864B1 (ko) * | 2008-08-01 | 2012-02-29 | 주식회사 베네비오 | 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물 |
| KR101112051B1 (ko) * | 2009-04-09 | 2012-02-14 | 주식회사 베네비오 | 비후성 반흔 또는 켈로이드 예방 또는 치료용 조성물 |
| KR20110092602A (ko) * | 2010-02-09 | 2011-08-18 | 주식회사 베네비오 | 플라스미노겐 활성 억제인자-1의 억제제 |
| SG10202110501RA (en) * | 2010-12-31 | 2021-11-29 | Abbott Lab | Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides |
| DE112013004483T5 (de) * | 2012-09-14 | 2015-06-03 | Robert Bosch Gmbh | Überprüfung einer Vorrichtung unter Verwenden eines Versperrens einer akustischen Öffnung |
| TW201438719A (zh) * | 2012-12-18 | 2014-10-16 | Abbott Lab | 改善壓力症狀之母乳寡糖 |
| WO2014100191A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
| DE102013208103A1 (de) | 2013-05-03 | 2014-11-06 | Siemens Aktiengesellschaft | Röntgenquelle und bildgebendes System |
| WO2016145628A1 (en) * | 2015-03-18 | 2016-09-22 | Nestec S.A. | Composition comprising siallyllactose for use in enhancing learning skills and memory function |
-
2017
- 2017-01-13 MY MYPI2018702452A patent/MY197561A/en unknown
- 2017-01-13 US US16/069,972 patent/US20190030053A1/en active Pending
- 2017-01-13 CN CN202511095571.2A patent/CN120643579A/zh active Pending
- 2017-01-13 CA CA3010338A patent/CA3010338C/en active Active
- 2017-01-13 CN CN201780006641.XA patent/CN108472305A/zh active Pending
- 2017-01-13 EP EP17738695.0A patent/EP3403655B1/en active Active
- 2017-01-13 CA CA3203927A patent/CA3203927A1/en active Pending
- 2017-01-13 JP JP2018536439A patent/JP7125348B2/ja active Active
- 2017-01-13 EP EP21154787.2A patent/EP3845233A1/en active Pending
- 2017-01-13 KR KR1020187023369A patent/KR20180099885A/ko not_active Ceased
- 2017-01-13 KR KR1020217017487A patent/KR20210079376A/ko not_active Ceased
- 2017-01-13 HK HK19100055.1A patent/HK1257689A1/zh unknown
- 2017-01-13 KR KR1020237023071A patent/KR102771814B1/ko active Active
- 2017-01-13 WO PCT/KR2017/000505 patent/WO2017123066A1/ko not_active Ceased
- 2017-01-13 MX MX2018008671A patent/MX389553B/es unknown
- 2017-01-13 SG SG11201805791RA patent/SG11201805791RA/en unknown
- 2017-01-13 ES ES17738695T patent/ES2946945T3/es active Active
- 2017-01-13 CN CN202511095689.5A patent/CN120661527A/zh active Pending
-
2018
- 2018-07-13 MX MX2022000945A patent/MX2022000945A/es unknown
-
2022
- 2022-08-12 JP JP2022128627A patent/JP7467543B2/ja active Active
-
2024
- 2024-04-03 JP JP2024059854A patent/JP2024081767A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210079376A (ko) | 2021-06-29 |
| EP3403655A4 (en) | 2019-08-07 |
| CN120661527A (zh) | 2025-09-19 |
| US20190030053A1 (en) | 2019-01-31 |
| CN108472305A (zh) | 2018-08-31 |
| WO2017123066A1 (ko) | 2017-07-20 |
| JP2022166164A (ja) | 2022-11-01 |
| MX2022000945A (es) | 2022-02-14 |
| SG11201805791RA (en) | 2018-08-30 |
| ES2946945T3 (es) | 2023-07-28 |
| KR20180099885A (ko) | 2018-09-05 |
| EP3845233A1 (en) | 2021-07-07 |
| MX2018008671A (es) | 2019-02-13 |
| KR20230107718A (ko) | 2023-07-17 |
| JP2019502718A (ja) | 2019-01-31 |
| JP7125348B2 (ja) | 2022-08-24 |
| CA3010338C (en) | 2023-08-22 |
| JP2024081767A (ja) | 2024-06-18 |
| CA3010338A1 (en) | 2017-07-20 |
| RU2018128408A (ru) | 2020-02-13 |
| CN120643579A (zh) | 2025-09-16 |
| EP3403655C0 (en) | 2023-06-07 |
| EP3403655B1 (en) | 2023-06-07 |
| HK1257689A1 (zh) | 2019-10-25 |
| KR102771814B1 (ko) | 2025-02-26 |
| JP7467543B2 (ja) | 2024-04-15 |
| RU2018128408A3 (enExample) | 2020-02-13 |
| CA3203927A1 (en) | 2017-07-20 |
| MY197561A (en) | 2023-06-23 |
| EP3403655A1 (en) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| CL2019001565A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico. | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
| CL2019000844A1 (es) | Compuesto de piridina. | |
| MX2018006503A (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| MX2019009185A (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2016013801A (es) | Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes. | |
| BR112022012126A2 (pt) | Compostos antelmínticos compreendendo uma estrutura quinolínica | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2018008157A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
| MX2019002607A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2019006940A (es) | Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. |